- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Crispr Therapeutics AG (CRSP)
Crispr Therapeutics AG stock price live, this page displays NASDAQ CRSP stock exchange data. View the CRSP premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Crispr Therapeutics AG real time stock price chart below.
What Is the Crispr Therapeutics AG Stock Price Today?
The Crispr Therapeutics AG stock price today is 56.46.
What Is the Stock Symbol for Crispr Therapeutics AG?
The stock ticker symbol for Crispr Therapeutics AG is CRSP.
Is CRSP the Same as $CRSP?
$CRSP is a common way to refer to the Crispr Therapeutics AG ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Crispr Therapeutics AG Trade On?
Crispr Therapeutics AG is listed and trades on the NASDAQ stock exchange.
Is Crispr Therapeutics AG a Good Stock to Buy?
Determining whether Crispr Therapeutics AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Crispr Therapeutics AG share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CRSP quote. (ISIN: CH0334081137)
What Is the Crispr Therapeutics AG Stock Price Today?
The Crispr Therapeutics AG stock price today is 56.46.
What Is the Stock Symbol for Crispr Therapeutics AG?
The stock ticker symbol for Crispr Therapeutics AG is CRSP.
Is CRSP the Same as $CRSP?
$CRSP is a common way to refer to the Crispr Therapeutics AG ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Crispr Therapeutics AG Trade On?
Crispr Therapeutics AG is listed and trades on the NASDAQ stock exchange.
Is Crispr Therapeutics AG a Good Stock to Buy?
Determining whether Crispr Therapeutics AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Crispr Therapeutics AG share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CRSP quote. (ISIN: CH0334081137)
56.81
-0.05(-0.09%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
56.37
59.38
52 wk Range
33.03
78.48
CRSP is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
56.3759.38
52 wk Range
33.0378.48
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CRSP Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
83.35
Upside
+46.71%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
- Form 8K CRISPR THERAPEUTICS AG For: 11 March
- Investing.com
- Form 8K CRISPR THERAPEUTICS AG For: 16 March
- Investing.com
- Form 8K CRISPR THERAPEUTICS AG For: 16 March
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Crispr Therapeutics AG SWOT Analysis
Market Valuation | Analyst price targets range from $42 to $105, averaging $74, reflecting varied perspectives on CRISPR's leadership position in gene editing and its potential to revolutionize treatment paradigms. |
Financial Outlook | With $1.86 billion in cash reserves despite projected negative EPS of -6.52 for FY1, CRISPR balances robust development funding against the challenges of commercializing novel therapies. |
Pipeline Potential | Delve into CRISPR's expanding therapeutic portfolio, from promising CTX310 data for dyslipidemia to strategic diversification into siRNA therapies for cardiovascular conditions. |
Pioneering Gene Editing | CRISPR Therapeutics stands at a critical juncture as its proprietary CRISPR/Cas9 platform transitions from clinical promise to commercial reality with Casgevy leading the way. |
Compare CRSP to Peers and Sector
Metrics to compare | CRSP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCRSPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.5x | −2.9x | −0.5x | |
PEG Ratio | 0.19 | −0.10 | 0.00 | |
Price / Book | 2.9x | 1.6x | 2.6x | |
Price / LTM Sales | 1,570.8x | 18.4x | 3.2x | |
Upside (Analyst Target) | 40.7% | 250.5% | 47.6% | |
Fair Value Upside | Unlock | 2.1% | 6.1% | Unlock |
Analyst Ratings
17 Buy
9 Hold
1 Sell
Ratings:
27 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 83.35
(+46.71% Upside)
Earnings
Latest Release
Feb 12, 2026
EPS / Forecast
-1.37 / -1.17
Revenue / Forecast
860K / 5.66M
People Also Watch
FAQ
What Is the Crispr Therapeutics (CRSP) Stock Price Today?
The Crispr Therapeutics stock price today is 56.81 USD.
What Stock Exchange Does Crispr Therapeutics Trade On?
Crispr Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Crispr Therapeutics?
The stock symbol for Crispr Therapeutics is "CRSP."
What Is the Crispr Therapeutics Market Cap?
As of today, Crispr Therapeutics market cap is 5.45B USD.
What Is Crispr Therapeutics's Earnings Per Share (TTM)?
The Crispr Therapeutics EPS (TTM) is -6.47.
When Is the Next Crispr Therapeutics Earnings Date?
Crispr Therapeutics will release its next earnings report on May 11, 2026.
From a Technical Analysis Perspective, Is CRSP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Crispr Therapeutics Stock Split?
Crispr Therapeutics has split 0 times.
How Many Employees Does Crispr Therapeutics Have?
Crispr Therapeutics has 393 employees.
What is the current trading status of Crispr Therapeutics (CRSP)?
As of Apr 15, 2026, Crispr Therapeutics (CRSP) is trading at a price of 56.81 USD, with a previous close of 56.86 USD. The stock has fluctuated within a day range of 56.37 USD to 59.38 USD, while its 52-week range spans from 33.03 USD to 78.48 USD.
What Is Crispr Therapeutics (CRSP) Price Target According to Analysts?
The average 12-month price target for Crispr Therapeutics is 83.35 USD, with a high estimate of 291 USD and a low estimate of 33 USD. 17 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +46.71% Upside potential.
What Is the CRSP Premarket Price?
CRSP's last pre-market stock price is 57.15 USD. The pre-market share volume is 7,670.00, and the stock has decreased by 0.29, or 0.51%.
What Is the CRSP After Hours Price?
CRSP's last after hours stock price is 57.00 USD, the stock has decreased by 0.14, or 0.25%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.